Skip to main content
Premium Trial:

Request an Annual Quote

GE to Commercialize Cytori's Stem Cell Technology in North America

NEW YORK (GenomeWeb News) – GE Healthcare and San Diego-based Cytori jointly announced today that GE will commercialize Cytori's StemSource technology in North America for the stem cell banking and research markets.

The StemSource technology automates and processes stem and regenerative cells found in adipose tissue and cryopreserves them directly for research purposes. The term of the pact is 18 months and begins in the current quarter. The agreement does not include Cytori's Celution System for cosmetic and reconstructive surgery, which is currently under Food and Drug Admin istration review.

The North American agreement follows a similar alliance signed between the firms in January covering 10 European countries. That deal includes both the StemSource and Celution technologies.

"Our US sales team, like that in Europe, is seeing growing customer demand for adipose-related cell technology, both from our existing stem cell banking customers as well as our research customers involved in the development of cell therapies," Konstantin Fiedler, general manager of cell technologies at GE Healthcare, said in a statement.

The Scan

Purnell Choppin Dies

Purnell Choppin, a virologist who led the Howard Hughes Medical Institute, has died at 91, according to the Washington Post.

Effectiveness May Decline, Data From Israel Suggests

The New York Times reports that new Israeli data suggests a decline in Pfizer-BioNTech SARS-CoV-2 vaccine effectiveness against Delta variant infection, though protection against severe disease remains high.

To See Future Risk

Slate looks into the use of polygenic risk scores in embryo screening.

PLOS Papers on Methicillin-Resistant Staphylococcus, Bone Marrow Smear Sequencing, More

In PLOS this week: genomic analysis of methicillin-resistant Staphylococcus pseudintermedius, archived bone marrow sequencing, and more.